Abstract:Duchenne muscular dystrophy (DMD) is the most prevalent herediatry disease in men, characterized by dystrophin deficiency, progressive muscle wasting, cardiac insufficiency, and premature mortality, with no effective therapeutic options. Here, we investigated whether adenine base editing can correct pathological non-sense point mutations leading to premature stop codons in the dystrophin gene. We identified 27 causative nonsense mutations in our DMD patient cohort. Treatment with adenine base editor (ABE) could restore dystrophin expression by direct A-to-G editing of pathological nonsense mutations in cardiomyocytes generated from DMD patient-derived induced pluripotent stem cells. We also generated two humanized mouse models of DMD expressing mutation-bearing exons 23 or 30 of human dystrophin gene. Intramuscular administration of ABE, driven by ubiquitous or muscle-specific promoters could correct these non-sense mutations in vivo, albeit with higher efficiency in exon 30, restoring dystrophin expression in skeletal fibers of humanized DMD mice. Moreover, a single systemic delivery of ABE with human sgRNA could induce body-wide dystrophin expression and improve muscle function in rotarod tests of humanized DMD mice. These findings demonstrate that ABE with human sgRNAs can confer therapeutic alleviation of DMD in mice, providing a basis for development of adenine base editing therapies in monogenic diseases.

Adenine base editing in mouse embryos and an adult mouse model of Duchenne muscular dystrophy

Adenine Base Editing in an Adult Mouse Model of Tyrosinaemia

Correction of human non-sense mutation via adenine base editing for Duchenne muscular dystrophy treatment in mouse

Adenine base editing-mediated exon skipping restores dystrophin in humanized Duchenne mouse model

Mitochondrial adenine base editing of mouse somatic tissues via adeno-associated viral delivery

Cytosine and Adenine Base Editing of the Brain, Liver, Retina, Heart and Skeletal Muscle of Mice Via Adeno-Associated Viruses

Adenine transversion editors enable precise, efficient A•T-to-C•G base editing in mammalian cells and embryos

Adenine Base Editing in vivo with a Single Adeno-Associated Virus Vector

In vivo mitochondrial base editing via adeno-associated viral delivery to mouse post-mitotic tissue

Engineering TALE-linked deaminases to facilitate precision adenine base editing in mitochondrial DNA

In vivo adenine base editing rescues adrenoleukodystrophy in a humanized mouse model

Single-Swap Editing for the Correction of Common Duchenne Muscular Dystrophy Mutations

In Vivo Adenine Base Editing Corrects Newborn Murine Model of Hurler Syndrome

Engineering a Precise Adenine Base Editor with Minimal Bystander Editing.

Mitochondrial DNA editing in mice with DddA-TALE fusion deaminases

Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing

In utero adenine base editing corrects multi-organ pathology in a lethal lysosomal storage disease

Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases

Therapeutic adenine base editing corrects nonsense mutation and improves visual function in a mouse model of Leber congenital amaurosis

Precision genome editing using cytosine and adenine base editors in mammalian cells

Mini-dCas13X–mediated RNA editing restores dystrophin expression in a humanized mouse model of Duchenne muscular dystrophy